Stockscreener 앱 받기
1.85
2.63%
-0.05
전일 마감가:
$1.90
열려 있는:
$1.92
하루 거래량:
964.88K
Relative Volume:
0.74
시가총액:
$294.15M
수익:
$10.00M
순이익/손실:
$-29.47M
주가수익비율:
-9.25
EPS:
-0.2
순현금흐름:
$-21.55M
1주 성능:
-7.50%
1개월 성능:
-9.31%
6개월 성능:
-30.71%
1년 성능:
-56.78%
1일 변동 폭
$1.81
$1.93
1주일 범위
$1.81
$2.15
52주 변동 폭
$1.47
$4.395
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
명칭
Mereo Biopharma Group Plc Adr
전화
4403330237300
주소
ONE CAVENDISH PLACE, LONDON
MREO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.85 | 302.28M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.76 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.33 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.30 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-27 | 개시 | JP Morgan | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2023-10-13 | 재개 | BTIG Research | Buy |
| 2022-08-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Needham | Buy |
모두보기
Mereo Biopharma Group Plc Adr 주식(MREO)의 최신 뉴스
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aberdeen Group plc Has $8.21 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Adage Capital Partners GP L.L.C. Has $3.83 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Frazier Life Sciences Management L.P. Increases Stock Holdings in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - FinancialContent
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Oklahoma City NewsThe Oklahoman - FinancialContent
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
About Us - FinancialContent
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo Biopharma Group Plc Adr (MREO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.05%
자본화:
|
볼륨(24시간):